Market Wire - Theravance Announces Initiation of Phase 2 Clinical Program with its MABA Compound in COPD
Posted by admin / Under Long Acting Beta Adrenoceptor Agonist
October 31, 2007 --
Theravance, Inc. (NASDAQ: THRX)announced today that GSK has initiated a Phase 2 clinical study ofGSK961081, an investigational bifunctional...
Published on Thursday 9th of February 2012 07:38:17 PM





Share this!